Dapirolizumab

• UNSPSC Description:

  Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus[1].

• Target Antigen:

  TNF Receptor

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Apoptosis

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/dapirolizumab.html

• Purity:

  99.40

• Smiles:

  [Dapirolizumab]

• References & Citations:

  [1]Furie RA, et al., Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford). 2021 Nov 3;60(11):5397-5407.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Clinical Information:

  Phase 3